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Letter to the Editor 
 
The extensive experience with mesenchymal stromal cells (MSCs) in the 
treatment of inflammatory disorders has provided convincing evidence to 
support their clinical efficacy in selected cases, especially in steroid-resistant 
acute graft-versus-host disease (GvHD)
1,2
. Although MSCs can directly induce 
immunosuppression through the secretion of soluble factors and contact-
mediated mechanisms, it is becoming clearer that the recruitment of recipient 
immunoregulatory networks is fundamental for delivering their therapeutic 
effects
3
. We have recently identified a novel mechanistic pathway by which 
MSCs mediate immunosuppression in GvHD
4
. Following contact with recipient 
cytotoxic cells, MSCs undergo in vivo apoptosis and are efferocytosed by 
phagocytes which are then induced to up-regulate indoleamine 2,3-
dioxygenase (IDO). Therefore, to accomplish MSC immunosuppression, patients 
must harbor activated cytotoxic cells and competent phagocytes. Whilst 
assessing the magnitude of MSC apoptosis induced by recipient cytotoxic cells 
can provide a biomarker predictive of clinical responses to MSC
4
, there are no 
tools to monitor the immunological effects of MSC following efferocytosis. In 
order to identify potential molecules for monitoring MSC immunological effects 
in patients, we interrogated the molecular and functional profile of human 
monocytes exposed to apoptotic MSCs (ApoMSCs).  
 
We isolated CD14
+
 monocytes from the peripheral blood of healthy donors 
(Supplementary Methods) because of their recognized role in engulfing dead 
MSCs
5
. MSCs were isolated and expanded as previously described
4
, and induced 
to undergo apoptosis using anti-Fas monoclonal antibody (CH11, Merck). 
ApoMSCs were characterized by Annexin-V (BD Biosciences) staining and 
immunoblotting for activated caspase-3 (Cell signaling) (Supplementary 
Methods & Supplementary Figure S1A-C). CellTrace™Violet (Thermo Fisher 
Scientific)-labelled (staining concentration: 1μM) monocytes were cultured with 
ApoMSCs labelled with 20 ng/mL pH-sensitive fluorescent dye pHrodo™Red
6
 
(Thermo Fisher Scientific). Efferocytosis was determined by quantitating 
pHrodo™Red fluorescence (mean fluorescence intensity, MFI) in monocytes 
using flow cytometry or CSU-X1 Spinning-Disk Confocal. Confocal data were 
processed with NIS Elements AR (Nikon) software. After 2 hours, monocytes 
rapidly engulfed ApoMSCs but not the non-apoptotic MSCs (Supplementary 
Figure S2A-B). ApoMSC efferocytosis was enhanced in the presence of 
lipopolysaccharide (LPS, 100μg/mL, Sigma-Aldrich) to model inflammation
7
 
(Figure 1A). When exposure to ApoMSCs was extended to 24 hours, the 
magnitude of efferocytosis was increased (Figure 1B-C). 
 
Apoptotic cell clearance is generally regarded as immune-silencing, although 
under particular circumstances, it can elicit immune responses
8
. To examine 
the immunomodulatory activity of ApoMSC-conditioned monocytes (ApoMSC-
Mono), we measured their ability to inhibit CD3/CD28-induced T-cell 
proliferation. CD3 T cells were isolated from the peripheral blood of healthy 
donors (Supplementary Methods). Monocytes were cultured with ApoMSCs for 8 
hours, and then added to CellTrace™Violet-labelled T cells (10
3
 cells/μL) 
stimulated with CD3/CD28 (Thermo Fisher Scientific) at 1:1 cell-to-bead ratio 
for 3 days. The proportion of proliferating T-cells was quantitated using flow 
cytometry. Remarkably, the ApoMSC-conditioned monocytes (ApoMSC-Mono) 
inhibited 50% of the T-cell proliferation in relative to the monocytes or 
ApoMSCs alone (Figure 1D). In contrast, ApoMSCs alone did not exhibit any 
inhibitory effect, suggesting that monocytes are required to inhibit the T-cell 
proliferation. Besides, it also excludes the possibility that there are any 
remaining non-apoptotic MSCs producing immunosuppressive effects. 
 
We then characterized the molecular profile of ApoMSC-Mono by evaluating the 
expression of selected molecules known to effect immunosuppression. 
CellTrace™Violet-labelled monocytes were cultured with ApoMSCs. After 8 
hours, the monocytes were stained with anti-human IDO-PE (eyedio), 
cyclooxygenase2 (COX2)-PE (AS67) and programmed death-ligand 1 (PD-L1)-
PE-Cy7 (29E.2A3) antibody and analyzed using flow cytometry. Notably, IDO, 
COX2 and PD-L1 were significantly up-regulated in ApoMSC-Mono (Figure 1E-
G). Examining the secreted soluble factors in culture supernatant, ELISA 
methods were used (all Thermo Fisher Scientific). We found the secretion of 
PGE
2 
and interleukin-10 (IL-10) was markedly increased, but tumor necrosis 
factor-α (TNF-α) was reduced compared to monocytes or ApoMSCs alone 
(Figure H-J). Overall the data suggest that monocytes exhibited a functional and 
molecular immunosuppressive phenotype following efferocytosis of ApoMSCs. 
To confirm the association between efferocytosis and the production of these 
immunosuppressive molecules, ApoMSCs were labelled with CellTrace™FarRed 
(APC, Thermo Fisher Scientific) (Figure 1K). The increased expression of COX2, 
IDO and PD-L1 was selectively detected in the monocytes engulfing ApoMSCs 
(APC
+
) (Figure 1K-L). 
 
Intriguingly, previous studies have indicated the ability of PGE
2
 to induce IDO, 
PD-L1 and IL-10
9–11
. Therefore, we investigated the dependence of these 
molecules on COX2/PGE
2 
activity. During the monocyte-conditioning, the 
selective COX2 inhibitor NS-398 (100 μM, Cayman) was added to inactivate 
COX2 in monocytes. The COX2 inhibition of monocytes was sufficient to 
prevent the induction of IDO, PD-L1 and IL-10, without interfering with 
efferocytosis (Figure 2A-E). Importantly, it significantly impaired the 
immunosuppressive activity of ApoMSC-Mono on in vitro T-cell proliferation 
(Figure 2F). Collectively, these findings reveal the ultimate role of efferocytosis-
induced COX2/PGE
2
 in delivering immunosuppression and its master role in 
regulating IDO, PD-L1 and IL-10 induced by efferocytosis. According to 
previous studies, PGE
2
 may enhance the expression of IDO or IL10 through the 
induction of cyclic adenosine monophosphate and protein kinase A 
activation
9,11
.  
 
Since COX2/PGE
2
 is the key effector of ApoMSC-induced immunosuppressive 
monocytes, we asked whether PGE
2
 levels could reflect the MSC immunological 
activity in GvHD patients receiving MSC treatment. This choice presents a major 
advantage compared to monitoring IDO activity. Although we previously 
identified IDO as the ultimate effector of ApoMSC in GvHD, the current method 
of determining IDO activity
12
 remains to be optimized. Soluble factors such as 
PGE
2
 serve as a simpler and more cost-effective approach for monitoring MSC 
immunological effects. 
 
Between July 2016 and August 2017, 8 severe steroid-resistant GvHD patients 
were treated with MSCs at the University Hospital Carl Gustav Carus (TU 
Dresden, Germany). MSCs were generated from the bone marrow of multiple 
third-party donors and expanded under good-manufacturing-practice 
conditions in Dresden Stem Cell Laboratory
13
. The treatment was made 
according to Regulation (European Commission) no. 1394/2007. The patient 
characteristics are summarized in Table 1. The diagnosis of GvHD was made 
according to standard criteria
14
. Clinical responses to MSCs, defined by at least 
1 stage reduction in any GvHD organ after infusion, were assessed 1 week after 
the infusion
1,13
. Donors and patients provided informed consent (Technische 
Universität Dresden, EK206082008).  
 
The average MSC dose was 1.68 ± 0.62 x 10
6
/kg (Mean ± SD), ranging from 
1.02 to 2.28 x 10
6
/kg. 4 patients achieved a partial response. One of the 
responder patients received two independent MSC infusions and assessed twice 
accordingly. 4 patients were non-responders. Serum samples were collected 
from patients 1 day before MSC infusion and then between 1 and 4 days 
(median 4 days) after the infusion and examined for PGE
2
 levels (Figure 2G, 
Supplementary Figure S3A-B). In order to compare the results across patients, 
we calculated the change in PGE
2
 levels before and after MSC infusion using the 
formula [PGE
2
after infusion
 - PGE
2
before infusion
]/PGE
2
before infusion 
x 100%]. As a result, 
the percentage of PGE
2
 increment was significantly higher in clinical responders 
compared to non-responders in which PGE
2
 levels remained unchanged (Figure 
2G). We are aware that the number of patients assessed is small and larger 
prospective studies are needed to validate our findings. Furthermore, it would 
be interesting to assess whether the phagocytes in responders and non-
responders exhibit any functional difference in efferocytosis. 
 
Overall, this study further strengthens the role of in vivo MSC apoptosis in 
delivering immunosuppression
4,15
. By showing that efferocytosis of ApoMSCs 
results in PGE
2
-dependent immunosuppression, our study is a step forward 
towards our understanding of the immunomodulatory role of MSC apoptosis. 
Therefore, we suggest that PGE
2
 monitoring could estimate the immunological 
activity of MSC therapy in GvHD patients. 
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Table 1. Patients’ characteristics 
 
Diagnosis Age &  gender 
Donor 
types 
GvHD  
Grade 
GvHD 
organs 
Pre-MSC 
therapy Conditioning Regimen  
MSC 
(x106/Kg) Response 
B-ALL 47, M MSD, PBSCT III 
Skin, 
Liver 
Steroids, 
ECP, CsA 
Etoposide phosphate;  
TBI 2.01 NR 
PMF 63, M MUD, PBSCT III Gut 
CsA, 
Prednisolone 
Busulfan  
Fludarabine  1.02 NR 
sAML 58, M MUD, PBSCT IV Gut 
CsA, 
Prednisolone Busilvex Fludarabine  1.02 NR 
MDS-EB2 67, M PBSCT IV Liver, Gut 
Steroids, 
Ruxolitinib 
Fludarabine; 
Busulfan 2.28 NR 
ALK-ALCL 45, M MSD, PBSCT IV 
Skin, 
Gut 
Prednisolone, 
Ruxolitinib, 
MSC, MMF 
Busilvex; 
Cyclophosphamide; 
Fludarabine 
2.23† 
& 
2.18‡ 
PR 
rAML 62, F MRD, PBSCT IV 
Liver, 
Gut 
CsA, 
Prednisolone 
Busilvex; 
Fludarabine 2.28 PR 
MM 68, M MUD, PBSCT IV Gut 
CsA, 
Prednisolone 
Rhenium-anti-CD66; 
Fludarabine; 
Treosulfane 
1.05 PR 
AML 58, M PBSCT IV 
Skin, 
Liver, 
Gut 
CsA, 
Prednisolon, 
ECP, 
Ruxolitinib 
Fludarabine; 
Busulfan 1.05 PR 
 
†: First dose  
‡: Second dose 
ALK-ALCL: Anaplastic Lymphoma Kinase-Negative Anaplastic Large Cell 
Lymphoma; AML: Acute Myeloid Leukemia; B-ALL: B-cell Acute Lymphoblastic 
Leukemia; CSA: Cyclosporine; ECP: Extracorporeal photopheresis; F: Female; M: 
Male; MDS-EB2: Myelodysplastic Syndrome with Excess Blasts Type 2; MM: 
Multiple Myeloma; MMF: Mycophenolate Mofetil; MRD: HLA-matched related 
donor; MSC: Mesenchymal stromal cells; MSD: HLA-matched sibling donor; 
MUD: HLA-matched unrelated donor; NR: non-responders; PBSCT: Peripheral 
Blood Stem Cell Transplant; PMF: Primary myelofibrosis; R: responders; rAML: 
Relapsed AML; sAML: Secondary AML; TBI: Total body irradiation 
 
  
Figure legends 
 
Figure 1. Efferocytosis of ApoMSCs polarizes monocytes into an 
immunosuppressive phenotype. (A) ApoMSCs were stained with 20 ng/mL 
pHrodo™ Red-succinimidyl ester (PE) whilst isolated monocytes were stained 
with 1μM CellTrace™Violet (V450). Monocytes were cultured with different 
amounts of ApoMSCs for 2 hours at 37°C, 5% CO
2
. 100μg/mL LPS was used to 
stimulate monocytes. The MFI (PE) within the monocytes population was 
measured as an indicator of efferocytosis, n=3. (B) MFI (PE) after 2 and 24 hours 
was compared among the different groups, n=3. (C) Confocal images of 
monocytes efferocytosing ApoMSCs after 24 hours in culture. The yellow arrows 
indicate the monocytes engulfing ApoMSCs whilst the white arrows indicate 
ApoMSCs alone. Bar represents 20 μm. (D) monocytes (2 x 10
5
/well) were co-
cultured with ApoMSCs (4 x 10
5
/well) for 8 hours. CellTrace™ Violet-labelled 
CD3 T cells (2 x 10
5
/well) were added to the cultures and stimulated by 
CD3/CD28 beads at a 1:1 cell:bead ratio for 3 days. The percentage of 
proliferating T cells were measured by flow cytometry according to the loss of 
fluorescence intensity due to cell division, n=4. (E-G) Intracellular and surface 
stainings were performed to examine different kinds of protein expressions 
including COX2, IDO and PD-L1 in monocytes. The COX2
high
, n=3
 
(E), IDO
high
, 
n=4 (F) and PD-L1
high
, n=3
 
(G) populations were gated according to the 
monocyte alone control (used as negative control). (H-J) ELISA was performed to 
assess the the amount of PGE
2
, n=4 (H), IL-10, n=3 (I) and TNF-α, n=6 (J) in 
cell culture supernatants. (K) To select the monocytes according to the 
efferocytosis, ApoMSCs were fluorescent-labelled with CellTrace™FarRed (APC
+
) 
whilst monocytes were labelled with CellTrace™Violet (V450
+
). APC
+
 Monocytes
 
were regarded as efferocytosis
+
 and APC
-
 monocytes were regarded as 
efferocytosis
-
. (L) Bar charts showing the difference of COX2
high
, IDO
high
 and PD-
L1
high
 population between the efferocytosis
+ 
and efferocytosis
- 
monocytes, n=3. 
Experimental data were expressed as mean ± SD. Unpaired t test was used to 
compare the mean differences between two samples. One-way ANOVA and 
post-hoc Tukey test were used to compare the mean differences among the 
samples (* p-values < 0.05; ** p-values < 0.01; *** p-values < 0.001; **** p-
values < 0.0001).  
  
Figure 2. Efferocytosis-induced COX2/PGE
2
 is the key effector molecule of 
immunosuppressive monocytes. (A) 100 μM NS-398 was added during the co-
culture of monocytes and ApoMSCs. After 8-hours, efferocytosis was evaluated 
using flow cytometry, n=3. As reported in A, PGE
2
, n=4 (B) and IL-10, n=4 (C) 
were evaluated in cell culture supernatant using ELISA, whilst IDO, n=5 (D) and 
PD-L1, n=3 (E) in monocytes were examined by flow-cytometry. (F) COX2 
activity in efferocytosing monocytes was inhibited by using 100 μM NS-398 
before adding them to CellTrace™ Violet-labelled CD3 T cells. Proliferation of T 
cells were measured and analyzed by flow cytometry, n=4. Experimental data 
were expressed as mean ± SD. One-way ANOVA and post-hoc Tukey test were 
used to compare the mean differences among the samples. (G) 8 steroid-
resistant GvHD patients receiving MSC were analyzed for serum PGE
2
 levels. The 
percentages of PGE
2
 increment [PGE
2
after infusion
 - PGE
2
before infusion
]/PGE
2
before infusion 
x 100%] were compared between clinical responders ( n=5) and non-
responders (■ n=4). Unpaired t test was used to compare the mean differences 
between two groups (* p-values < 0.05; ** p-values < 0.01; ns, not significant).  
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Supplementary Methods 
 
MSC isolation and culture 
Human bone marrow-derived MSCs were isolated from the bone marrow aspirate 
taken from the iliac crest of healthy donor, which was obtained from the Imperial 
College Healthcare Tissue Bank (ICHTB, HTA license 12275). ICHTB is supported 
by the National Institute for Health Research (NIHR) Biomedical Research Centre 
based at Imperial College Healthcare NHS Trust and Imperial College London. 
ICHTB is approved by the UK National Research Ethics Service to release human 
material for research (12/WA/0196), and the samples for this project were issued 
from the sub-collection. Informed consent was obtained in accordance with 
ICHTB requirements and procedures were carried out in accordance with relevant 
guidelines and regulations. Mononuclear cells was first plated (10 - 25 x 106 per 
636 cm2) in MEM- (Thermo Fisher Scientific) containing 5% (v/v) human platelet 
lysate (Cook Regentec) and 1 U/mL heparin (Wockhardt) at 37°C, 5% CO2. Non-
adherent cells were removed after washing of PBS (Thermo Fisher Scientific) and 
replenishing the culture medium. When adherent MSCs reached approximately 
70% to 90% confluence of culture flask, they were detached using Trypsin-EDTA 
(0.05%) with phenol red (Thermo Fisher Scientific) and expanded. MSCs at 
passage 3 to 7 (all from the same MSC donor) were used for experiments.  
 
Generation of ApoMSCs 
5 x 105 MSCs were treated with 10 μg/mL anti-Fas stimulating monoclonal 
antibody (CH11, Merck) in complete RPMI-1640 for 24 hours at 37°C, 5% CO2. 
Caspase activation was confirmed using pan-caspase inhibitor Z-VAD-FMK (50 
μM, R&D Systems) under PE-Annexin V and 7-AAD (BD) staining using flow 
cytometry and caspase-3 (active) immunoblotting. 
 
Protein extraction and Immunoblotting 
Cell lysates from MSCs and ApoMSCs were homogenized using 100 μL 
radioimmunoprecipitation assay buffer with phenylmethanesulfonyl fluoride and 
protease Inhibitors (all Thermo Fisher Scientific). After several vortexing and 
incubation on ice for 30 minutes, the protein extracts were obtained after 
centrifuging at 10,000 xg for 15 mins at 4°C. The amount of protein was 
determined by bicinchoninic acid protein assay kit (Thermo Fisher Scientific). 
Protein standards were prepared using bovine serum albumin (BSA) (Sigma-
Aldrich) and deionized water. Amount of protein in samples was measured by 
NanoDropTM 1000 Spectrophotometer (Thermo Fisher Scientific). Deionized 
water was used as blank. 20 μg protein per sample was prepared in laemmli 
buffer (Thermo Fisher Scientific) and boiled at 100°C for 5 mins. Then, samples 
with equal protein amount were electrophoresed on 5-10% SDS-polyacrylamide 
gels and then transferred onto activated nitrocellulose membranes. After 
electroblotting, the membrane was washed by Tris-buffered saline-Tween20 
(TBS-T) and 5 % (w/v) non-fat milk in TBS-T was used to block the membrane for 
1 hour at room temperature. Discarding the blocking buffer, primary anti-
caspase-3 (dilution 1:500, Cell Signaling Technology) in 3% BSA (w/v) TBS-T was 
added for overnight probing at 4°C. Anti-α-tubulin antibody (dilution 1:500, 
Santa Cruz Biotechnology) was used as protein loading control. Secondary 
antibody conjugated with horseradish peroxidase in 5% non-fat milk TBS-T 
(dilution 1:1000) was added for 1-hour incubation at room temperature followed 
by TBS-T washing. Protein expression was detected using Pierce™ ECL Western 
Blotting Substrate (Thermo Fisher Scientific). Membrane was imaged using Azure 
c300 Chemiluminescent Western Blot Imaging System. 
 
Isolation of human PBMCs, monocytes and CD3 T cells 
Human blood samples are purchased from the National Health Service (NHS) 
Blood and Transplant (UK) with the non-clinical account number (P243) for 
research purposes. For this project being conducted in England, no ethical 
approval is needed from the NHS Research Ethics Committee. Human peripheral 
blood mononuclear cells (PBMCs) were isolated from healthy volunteers’ blood 
using Ficoll-PaqueTM (Sigma-Aldrich). The storage of isolated human PBMCs is 
under the Human Tissue Authority (UK) license no.11023. To obtain monocytes 
and CD3 T cells, PBMCs were subjected to Pan Monocyte Isolation Kit II and CD3 
MicroBeads (Miltenyi), respectively. After purification, CD14+ (61D3) cells were 
91.9 ± 0.7 % (n=4), whilst CD3+ (UCHT1) cells were 96.7 ± 0.6% (n=3) compared 
to the isotype controls. 
 
Statistical analysis 
Statistical analysis was performed using PRISM version 6.0 (GraphPad, USA). 
Experimental data were expressed as mean ± SD from at least three 
determinations. One-way ANOVA and post-hoc Tukey test were used to compare 
the mean differences when there are more than two samples. Unpaired t test was 
used to compare the mean differences between two samples. p values less than 
0.05 were considered statistically significant. 
 
  
Supplementary Figures 
 
 
 
Supplementary Figure 1. Human bone marrow MSCs undergo Fas-stimulated 
apoptosis via caspase activation. (A) 5 x 105 MSCs were treated with 10 μg/mL 
anti-Fas stimulating monoclonal antibody (CH11) for 24 hours to induce 
apoptosis. Apoptosis was assessed using the PE-annexin-V and 7-AAD by flow 
cytometry. Gating strategy and representative plots annotated with experiment 
data (mean ± SD in each quadrant) are shown, n=5. Pan-caspase inhibitor Z-
VAD-FMK (50μM) was added during the incubation to examine the dependence 
of caspase activation following the Fas-stimulation (B). The percentage of 
apoptotic cells was calculated as Annexin-V+ cells by adding the percentage of 
cell population in the Q2 upper-right quadrant (Annexin-v+ and 7-AAD+) and Q2 
lower-right quadrant (Annexin-v+ and 7-AAD-). Experimental data were 
expressed as mean ± SD, n=5. One-way ANOVA and post-hoc Tukey test were 
used to compare the mean differences among the samples (**** p-values < 
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0.0001). (C) The protein lysates were extracted and performed immunoblotting 
with anti-caspase-3 (dilution 1:500) and anti-α-tubulin antibody (dilution 
1:500). Dilution of secondary antibody conjugated with horseradish peroxidase 
was 1:1000. The image is the representative from 3 experiments.  
  
 
Supplementary Figure 2. Efferocytosis is selective for ApoMSCs. (A) LPS-activated 
monocytes were co-cultured with non-apoptotic MSCs (Live MSCs, untreated; 
Fas-ZVAD-MSC, MSCs treated with anti-Fas and caspase inhibitor Z-VAD-FMK) 
or ApoMSCs under the same co-culture ratio (MSCs: Monocytes 2:1) for 2 hours 
before efferocytosis was assessed. All groups of MSCs were fluorescent-labelled 
with 20 ng/mL pH-sensitive fluorescent dye pHrodo™Red. Monocytes 
undergoing efferocytosis were considered as V450+ population acquiring the PE 
fluorescence (Q2 upper-right quadrant: V450+ and PE+). (B) Percentage of 
efferocytosis was determined according to the population of Q2 quadrant. 
Experimental data were expressed as mean ± SD, n=4. One-way ANOVA and 
post-hoc Tukey test were used to compare the mean differences among the 
samples (** p-values < 0.01; ns, not significant). 
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Supplementary Figure 3. Change of serum PGE2 level in responder (A) and non-
responder (B) GvHD patients. For each patient, the sera before MSC treatment 
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Changes of serum PGE2 in NRB 
(Pre MSCs) and after MSC treatment (Post MSCs) have been examined for the level 
of PGE2 using ELISA kit.  
 
